At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 11 enrolled
Drug / intervention
Venoferdrug
Likely dose
Venofer 7mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Single-Dose Pharmacokinetics of Venofer (Iron Sucrose Injection) in Non-Dialysis Dependent (NDD-CKD) Pediatric Patients Receiving or Not Receiving Erythropoiesis Stimulating Agents (ESA's)
In Brief
A Phase 2 clinical trial evaluating Venofer for Anemia. Completed, enrolled 11 participants across 1 site.
Detailed Summary
The primary objective of this study is to assess the pharmacokinetics of Venofer (Iron Sucrose Injection) in NDD-CKD pediatric patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnemia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2006
Primary CompletionJul 2008
First PostedJul 2008
Study CompletionJan 2010
TodayJul 2026
First PostedJul 23, 2008
Enrollment StartJan 1, 2006
Primary CompletionJul 1, 2008
Study CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 17.9 years ago
Interventions
Venoferdrug
Single dose of 7mg intravenous (IV) of iron per kg of body weight for a maximum of 200mg iron IV.